Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Lupin has informed that it has enclosed a Press Release on 19th February 2021 as regards receipt of USFDA approval for the Company's Droxidopa Capsules, 100 mg, 200 mg and 300 mg, to market a generic equivalent of Northera Capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1915.55 |
| Dr. Reddys Labs. | 1368.75 |
| Cipla | 1471.25 |
| Zydus Lifesciences | 1148.90 |
| Lupin | 2490.00 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: